New Pill Offers Hope for Pancreatic Cancer

A breakthrough drug called daraxonrasib is giving advanced pancreatic cancer patients a lifeline, doubling median survival to over 13 months compared to under 7 months with chemo—while slashing side effects and improving quality of life. Doctors are emotional about the results, noting patients stayed on treatment longer and could even become surgical candidates. The FDA is fast-tracking approval, and some patients are already accessing it. This could redefine standard care for metastatic pancreatic cancer—and bring real hope after decades of limited progress. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9c241174d758cfa5